New cancer clinical trial: A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Published on: July 27, 2018 at 12:00PM
Condition:   Ovarian Cancer
Interventions:   Drug: Niraparib;   Drug: TSR-042;   Drug: Placebo
Sponsors:   Tesaro, Inc.;   European Network of Gynaecological Oncological Trial Groups (ENGOT)
Not yet recruiting
https://ift.tt/2Ai6R3h